Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 17/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5729389 | 1.00 | P2RY12 (0.46) | P2RY12KDM1AADORA2A | |
| SCHEMBL6075252 | 1.00 | P2RY12 (0.46) | P2RY12KDM1AADORA2A | |
| SCHEMBL5729393 | 1.00 | P2RY12 (0.46) | P2RY12KDM1AADORA2A | |
| SCHEMBL14709136 | 0.83 | KDM1A (0.58) | P2RY12KDM1AADORA2A | |
| SCHEMBL6844522 | 0.81 | P2RY12 (0.47) | P2RY12KDM1A | |
| SCHEMBL6626046 | 0.81 | P2RY12 (0.47) | P2RY12KDM1A | |
| SCHEMBL14709077 | 0.81 | KDM1A (0.44) | P2RY12KDM1A | |
| SCHEMBL15859656 | 0.79 | P2RY12 (0.43) | P2RY12 | |
| SCHEMBL15757983 | 0.79 | P2RY12 (0.43) | P2RY12 | |
| SCHEMBL1509197 | 0.79 | P2RY12 (0.43) | P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335919-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | ASTRAZENECA AB (SE) | 2006-11-15 | — | — | EP | disclosed |
| US-7034032-B2 | Cyclopentan-2-ol-1-yl-[1,2,3]triazolo[4,5-D]pyrimidine compounds | ASTRAZENECA AB (SE) | 2006-04-25 | — | — | US | disclosed |
| US-20040023988-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023988-A1 | Novel compounds | DPYD, TYMP, TYMS | P2RY12 132/4885KDM1A 2172/4885ADORA2A 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.